[Control should be counteracted].
作者信息
Gøtzsche Peter C
出版信息
Ugeskr Laeger. 2011 Aug 15;173(33):1991.
PMID:21969953
Abstract
摘要
相似文献
1
[Control should be counteracted].[应抵制控制]。
Ugeskr Laeger. 2011 Aug 15;173(33):1991.
2
[Drug industry and publication practice].[制药行业与出版实践]
Ugeskr Laeger. 2011 Aug 15;173(33):1989.
3
[Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
Ugeskr Laeger. 2007 Nov 19;169(47):4054-7.
4
[Glitazones in type 2 diabetes--documented risks, uncertain benefits].2型糖尿病中的格列酮类药物——已证实的风险，不确定的益处
Lakartidningen. 2007;104(43):3198-200.
5
[New, expensive antidiabetics for the treatment of type-2 diabetes--pro].[用于治疗2型糖尿病的新型昂贵抗糖尿病药物——支持观点]
Dtsch Med Wochenschr. 2010 May;135(18):922. doi: 10.1055/s-0030-1253679. Epub 2010 Apr 27.
6
7
The dogma of "tight control": beyond the limits of evidence.“严格控制”的教条：超出证据的限度
Arch Intern Med. 2006;166(15):1671-2; author reply 1672. doi: 10.1001/archinte.166.15.1671-b.
8
[Type 2 diabetes: is the treatment based on evidence?].
Rev Med Suisse. 2010 Sep 1;6(260):1624-5; author reply 1625.
9
The evidence for insulin lispro.赖脯胰岛素的证据。
CMAJ. 1998 Dec 1;159(11):1353-5.
10
Warner-Lambert voluntarily withdraws Rezulin.华纳-兰伯特公司自愿撤回曲格列酮。
Diabetes Technol Ther. 2000 Summer;2(2):290.
Zotero 插件